60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

<p> Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patients The previously announced Type C meeting with FDA has been rescheduled by FDA from January 15 to January 17, 2024, due to a federal holiday WASHINGTON, Dec. 26, 2023 (GLOBE NEWSWIRE) […]</p>
<p>The post <a href="https://forextv.com/top-news/60-degrees-pharma-announces-irb-approval-of-phase-iia-study-to-evaluate-tafenoquine-for-babesiosis-an-emerging-tick-borne-disease-type-c-meeting-re-scheduled-by-fda-to-january-17-2024/">60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>